-
Hospira, Inc. v. Fresenius Kabi USA, LLC DC CAFC
- 1:16-cv-00651
- N.D. Ill.
- Judge: Rebecca R. Pallmeyer
- Filed: 01/15/2016
- Closed: 12/17/2018
- Latest Docket Entry: 04/22/2022
- PACER
1
Plaintiff
1
Defendant
2
Accused
Products
4
Patents-in-Suit
1,068
Days in
Litigation
-
Hospira, Inc. v. Fresenius Kabi USA, LLC DC CAFC
- 1:16-cv-00651
- N.D. Ill.
- Judge: Rebecca R. Pallmeyer
- Filed: 01/15/2016
- Closed: 12/17/2018
- Latest Docket Entry: 04/22/2022
- PACER
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 3 |
The ready to use liquid pharmaceutical composition of claim 2, wherein the sodium chloride is present at a concentration of about 0.9 weight percent.
|
Invalid
Entry 184 |
| 4 |
The ready to use liquid pharmaceutical composition of claim 1, wherein the composition is formulated as a total volume selected from the group consisting of 20 mL, 50 mL and 100 mL.
|
Invalid
Entry 184 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 4 |
The ready to use liquid pharmaceutical composition of claim 1, wherein the dexmedetomidine or pharmaceutically acceptable salt thereof is at a concentration of about 1 to about 7 ug/mL.
|
Invalid
Entry 184 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 5 |
The method of claim 1, wherein the dexmedetomidine or pharmaceutically acceptable salt thereof is at a concentration of about 4 μg/mL.
|
Invalid
Entry 184 |
-
Infringement
Fresenius KABI USA LLC
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| exmedetomidine hydrochloride products | US 8,242,158 B1 |
3, 4
|
No infringement
Entry 184
|
| exmedetomidine hydrochloride products | US 8,338,470 B1 |
4
|
No infringement
Entry 184
|
| exmedetomidine hydrochloride products | US 8,455,527 B1 |
5
|
No infringement
Entry 184
|
